Regression of prostate cancer xenografts by RLIP76 depletion

Biochemical Pharmacology

Volumn 77, Issue 6, 2009, Pages 1074-1083

  Singhal, Sharad S ^a   Roth, Cherice ^a   Leake, Kathryn ^a   Singhal, Jyotsana ^a   Yadav, Sushma ^a   Awasthi, Sanjay ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer; Drug resistance; Glutathione conjugate transport; RLIP76; Xenografts

Indexed keywords

DOXORUBICIN; PROTEIN RLIP 76; RAL PROTEIN; RLIP 76 ANTIBODY; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; XENOGRAFT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL LINE, TUMOR; GTPASE-ACTIVATING PROTEINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGORIBONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; REMISSION INDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60649110014     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.11.013     Document Type: Article

References (42)

1. Sirotnak F.M., Wendel H.G., Bornmann W.G., Tong W.P., Miller V.A., Scher H.I., et al. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 6 (2000) 3705-3712
2. Zhang Y., Bressler J.P., Neal J., Lal B., Bhang H.E., Laterra J., et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 67 (2007) 9389-9397
3. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 118 (2007) 3003-3006
4. Shen M.M., and Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 67 (2007) 6535-6538
5. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118 (2008) 3051-3064
6. Pusztai L., Wagner P., Ibrahim N., Rivera E., and Theriault R. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104 (2005) 682-691
7. Modok S., Mellor H.R., and Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6 (2006) 350-354
8. Robey R.W., Shukla S., Finley E.M., Oldham R.K., Barnett D., Ambudkar S.V., et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75 (2008) 1302-1312
9. Shukla S., Wu C.P., and Ambudkar S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 4 (2008) 205-223
10. Singhal J., Singhal S.S., Yadav S., Warnke M., Yacoub A., Dent P., et al. RLIP76 in defense of radiation poisoning. Int J Rad Oncol Biol Phys 72 (2008) 553-561
11. Jullien-Flores V., Dorseuil O., Romero F., Letourneur F., Saragosti S., Berger R., et al. Bridging Ral-GTPase to Rho-pathways. RLIP76, a Ral-effector with CDC42/RacGTPase activating protein activity. J Biol Chem 270 (1995) 22473-22477
12. Awasthi S., Cheng J., Singhal S.S., Saini M.K., Pandya U., Pikula S., et al. Novel function of human RLIP76: ATP-dependent transport of glutathione-conjugates and doxorubicin. Biochemistry 39 (2000) 9327-9334
13. Singhal S.S., Singhal J., Yadav S., Dwivedi S., Boor P., Awasthi Y.C., et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76. Cancer Res 67 (2007) 4382-4389
14. Awasthi Y.C., Garg H.S., Dao D.D., Partridge C.A., and Srivastava S.K. Enzymatic conjugation of erythrocyte glutathione with 1-chloro-2,4-dinitrobenzene: the fate of glutathione conjugate in erythrocytes and the effect of glutathione depletion on hemoglobin. Blood 58 (1981) 733-738
15. Singhal S.S., Singhal J., Sharma R., Singh S.V., Zimniak P., Awasthi Y.C., et al. Role of RLIP76 in lung cancer doxorubicin-resistance. I. The ATPase activity of RLIP76 correlates with doxorubicin and 4HNE-resistance in lung cancer cells. Int J Oncol 22 (2003) 365-375
16. Awasthi S., Singhal S.S., Sharma R., Zimniak P., and Awasthi Y.C. Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between G-protein and tyrosine-kinase signaling and drug-resistance. Int J Cancer 106 (2003) 635-646
17. Stuckler D., Singhal J., Singhal S.S., Yadav S., Awasthi Y.C., and Awasthi S. RLIP76 transports vinorelbine and mediates drug-resistance in non-small cell lung cancer. Cancer Res 65 (2005) 991-998
18. Singhal S.S., Yadav S., Singhal J., Zajac E., Awasthi Y.C., and Awasthi S. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 70 (2005) 481-488
19. Singhal S.S., Awasthi Y.C., and Awasthi S. Regression of melanoma in a murine model by RLIP76-depletion. Cancer Res 66 (2006) 2354-2360
20. Awasthi S., Singhal S.S., Srivastava S.K., Zimniak P., Bajpai K.K., Saxena M., et al. Adenosine-triphosphate-dependent transport of doxorubicin, daunomyicn, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 93 (1994) 958-965
21. Singhal S.S., Yadav S., Drake K., Singhal J., and Awasthi S. Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem 283 (2008) 19714-19729
22. 4 in cancer cells: implications in drug-resistance. Int J Cancer 112 (2004) 934-942
23. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., et al. Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
24. Lautier D., Canitrot Y., and Deeley R.G. Cole SPC. Multidrug-resistance mediated by the multidrug-resistance protein (MRP) gene. Biochem Pharmacol 52 (1996) 967-977
25. Gottesman M.M., and Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug-transporter. Annu Rev Biochem 62 (1993) 385-427
26. Awasthi S., Singhal S.S., Singhal J., Cheng J., Zimniak P., and Awasthi Y.C. Role of RLIP76 in lung cancer doxorubicin-resistance. II. Doxorubicin-transport in lung cancer by RLIP76. Int J Oncol 22 (2003) 713-720
27. Hipfner D.R., Mao Q., Qiu W., Leslie E.M., Gao M., Deeley R.G., et al. Monoclonal-antibodies that inhibit the transport function of the 190-kDa multidrug-resistance protein, MRP. Localization of their epitopes to the nucleotide-binding-domains of the protein. J Biol Chem 274 (1999) 15420-15426
28. Kokubu N., Cohen D., and Watanabe T. Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal-antibody against P-glycoprotein. Biochem Biophys Res Commun 230 (1997) 398-401
29. Blakey D.C., Westwood F.R., Walker M., Hughes G.D., Davis P.D., Ashton S.E., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8 (2002) 1974-1983
30. Vegesna V., O'Kelly J., Said J., Uskokovic M., Binderup L., and Koeffle H.P. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 23 (2003) 283-289
31. Vallabhajosula S., Smith-Jones P.M., Navarro V., Goldsmith S.J., and Bander N.H. Radio-immunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 58 (2004) 145-155
32. Smith P.C., and Keller E.T. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48 (2001) 47-53
33. Anai S., Goodison S., Shiverick K., Iczkowski K., Tanaka M., and Rosser C.J. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther 17 (2006) 975-984
34. Liu E.S., Luk S.C., Leung E.T., Lee W.H., Yuen W.F., Kwok K.M., et al. Effect of CKBM on prostate cancer cell growth in vitro and in vivo. J Chemother 20 (2008) 246-252
35. Frydman B., Blokhin A.V., Brummel S., Wilding G., Maxuitenko Y., Sarkar A., et al. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice. J Med Chem 46 (2003) 4586-4600
36. El-Zawahry A., McKillop J., and Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 5 (2005) 2
37. Low J.C., Wasan K.M., Fazli L., Eberding A., Adomat H., and Guns E.S. Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts. Cancer Chemother Pharmacol 60 (2007) 821-829
38. Casarez E.V., Dunlap-Brown M.E., Conaway M.R., and Amorino G.P. Radio-sensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models. Cancer Res 67 (2007) 8316-8324
39. Patel M.I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R.A., et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11 (2005) 1999-2007
40. Awasthi S., Singhal S.S., Yadav S., Singhal J., Drake K., Nadkar A., et al. RLIP76 is a major determinant of radiation-sensitivity. Cancer Res 65 (2005) 6022-6028
41. Oosterhoff J.K., Penninkhof F., Brinkmann A.O., Grootegoed J.A., and Blok L.G. POB1 is down-regulated during human prostate cancer progression and inhibits growth factor signaling in prostate cancer cells. Oncogene 22 (2003) 2920-2925
42. Rosse C., L'Hoste S., Offner N., Picard A., and Camonis J.H. RLIP, an effector of the Ral-GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J Biol Chem 278 (2003) 30597-30604